Hemogenyx Pharmaceuticals (HEMO) RNS Announcements

Add to Alert list
Date Time Source Announcement
30 Oct 2024 07:00 AM
RNS
Schedule for Phase I Clinical Trial Opening
02 Oct 2024 11:19 AM
RNS
Strategic Investment from Prevail Partners, LLC
27 Sep 2024 07:00 AM
RNS
Half-year Report
09 Sep 2024 07:00 AM
RNS
FLT3 Assay Ready for Phase I Trials at MD Anderson
02 Sep 2024 07:00 AM
RNS
CDX Development Update
28 Aug 2024 07:00 AM
RNS
Presentation at CBD S&T Conference
29 Jul 2024 07:00 AM
RNS
Macrophage-Directed Therapies Summit Presentation
27 Jun 2024 04:39 PM
RNS
Result of Annual General Meeting
17 Jun 2024 07:00 AM
RNS
Operations Update
03 Jun 2024 07:00 AM
RNS
Posting of Annual Report & Notice of AGM
25 Apr 2024 07:00 AM
RNS
Final Results
28 Mar 2024 07:00 AM
RNS
Total Voting Rights
29 Feb 2024 07:00 AM
RNS
Placing to Raise US$4.2 million
16 Feb 2024 07:00 AM
RNS
CBR Brain Delivery
14 Feb 2024 07:00 AM
RNS
CBR Intranasal Delivery
09 Feb 2024 07:00 AM
RNS
FDA Consents to Phase I Trials of HEMO-CAR-T
02 Feb 2024 07:00 AM
RNS
Approval and Issuance of U.S. Conditioning Patent
16 Jan 2024 07:00 AM
RNS
Submission of Complete Response to Clinical Hold
08 Jan 2024 07:00 AM
RNS
HEMO-CAR-T Process Qualification Run Completed
28 Nov 2023 12:19 PM
RNS
Placing to Raise £534,375
27 Nov 2023 07:00 AM
RNS
CBR Expanded to Treatment of Cancer
15 Nov 2023 07:00 AM
RNS
Lentivirus Re-manufacturing Completed
31 Oct 2023 07:00 AM
RNS
Total Voting Rights
28 Sep 2023 12:28 PM
RNS
Half-year Report
18 Sep 2023 07:00 AM
RNS
Strategic Investment from Prevail Partners, LLC
14 Sep 2023 07:00 AM
RNS
Clinical Hold Lift Plan is accepted by FDA
08 Sep 2023 05:11 PM
RNS
CBR Patent Application Update
10 Jul 2023 07:00 AM
RNS
Full FDA Review for HEMO-CAR-T IND
30 Jun 2023 04:07 PM
RNS
Result of Annual General Meeting
02 Jun 2023 02:01 PM
RNS
Posting of Annual Report & Notice of AGM
02 Jun 2023 11:24 AM
RNS
Clinical Hold on IND for HEMO-CAR-T
09 May 2023 07:00 AM
RNS
Submission of IND for HEMO-CAR-T
28 Apr 2023 10:05 AM
RNS
Equity Incentive Pool Increase and Option Grant
28 Apr 2023 07:00 AM
RNS
Final Results for the Year Ended 31 December 2022
23 Mar 2023 01:32 PM
RNS
HEMO-CAR-T Analytical Release Tests Completed
28 Feb 2023 07:00 AM
RNS
Total Voting Rights
07 Feb 2023 02:30 PM
RNS
Admission of Shares to Official List
26 Jan 2023 09:05 AM
RNS
Second Price Monitoring Extn
26 Jan 2023 09:00 AM
RNS
Price Monitoring Extension
26 Jan 2023 07:00 AM
RNS
Placing to Raise £4,056,250
23 Jan 2023 07:00 AM
RNS
HEMO-CAR-T 3rd Process Qualification Run Completed
16 Jan 2023 04:40 PM
RNS
Second Price Monitoring Extn
16 Jan 2023 04:35 PM
RNS
Price Monitoring Extension
13 Jan 2023 11:05 AM
RNS
Second Price Monitoring Extn
13 Jan 2023 11:00 AM
RNS
Price Monitoring Extension
12 Jan 2023 04:40 PM
RNS
Second Price Monitoring Extn
12 Jan 2023 04:35 PM
RNS
Price Monitoring Extension
12 Jan 2023 02:05 PM
RNS
Second Price Monitoring Extn
12 Jan 2023 02:00 PM
RNS
Price Monitoring Extension
10 Jan 2023 04:35 PM
RNS
Price Monitoring Extension

Hemogenyx Pharmaceuticals is a publicly traded company (LSE: HEMO) headquartered in London, with its US operating subsidiaries, Hemogenyx Pharmaceuticals LLC and Immugenyx LLC, located in New York City at its state-of-the-art research facility.

Hemogenyx Pharmaceuticals PLC is a preclinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies and treatments for blood diseases, like leukemia and lymphoma.

Hemo share price launched on LSE at 3p in 2017.

UK 100

Latest directors dealings